Strata Health

stratahealth.com

With over 15 years of experience developing and delivering custom software for health and social services, Strata Health is focused on improving the patient experience around the globe. Intelligent matching and referral solutions help healthcare providers increase productivity, achieve greater operational efficiencies, and create more positive outcomes for patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

KYAN THERAPEUTICS EXCLUSIVELY ENTERS LICENSE AGREEMENT WITH GEORGETOWN UNIVERSITY FOR AI-POWERED CANCER DRUG DEVELOPMENT

KYAN Therapeutics | September 24, 2020

news image

KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors. KYAN has already commenced preclinical development of the lead candidate, which has been designated as KYAN-001, with early positive results. In vitro and in vivo studies of KYAN-001 have shown high efficacy for Multiple Myeloma and Prostate ...

Read More

Industry Outlook

ATTOVIA THERAPEUTICS LAUNCHES WITH $60 MILLION SERIES A FINANCING TO UNLOCK POTENTIAL OF NOVEL BIPARATOPIC NANOBODY PLATFORM

Globenewswire | June 21, 2023

news image

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of diseases, and Frazier Life Sciences, announced the launch of Attovia Therapeutics, a newly formed company focused on creating a pipeline of biotherapeutics in immune-mediated disease and cancer. The company, based on Attobody™, Alamar’s novel proprietary biparatopic nanobody platform, concurrently closed a $60 million Series A financing led by Frazier and joined by venBio and Illumin...

Read More

MedTech

ROCHE SIGNS AN AGREEMENT WITH SYSMEX TO BRING HAEMATOLOGY TESTING INNOVATIONS GLOBALLY

Roche | January 25, 2021

news image

Roche declares that, on 14 December, 2020, it marked a Global Business Partnership Agreement* (GBP) with Sysmex. Under this new system, the gatherings restored their obligation to the long standing Distribution, Sales and Service (DSS) arrangement, permitting Roche to keep on disseminating Sysmex hematology items, including instruments and reagents. This GBP sees the presentation of an IT Solutions Collaboration Agreement. In the recently characterized joint effort, the two organizations have co...

Read More

Cell and Gene Therapy, Industrial Impact

BIO-TECHNE ANNOUNCES COMPLETION OF AND GENE THERAPY CATAPULT ANALYTICAL TECHNOLOGY (PAT) CONSORTIUM

Bio-Techne Corporation | March 20, 2023

news image

Bio-Techne Corporation announced it has completed its participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year collaboration involving 24 partner companies, technology providers, therapy developers, and charities. The Catapult PAT consortium is the first initiative of this scale and functional expertise with member companies and organizations collaborating to develop cell and gene therapy-specific process analytical technolog...

Read More
news image

KYAN THERAPEUTICS EXCLUSIVELY ENTERS LICENSE AGREEMENT WITH GEORGETOWN UNIVERSITY FOR AI-POWERED CANCER DRUG DEVELOPMENT

KYAN Therapeutics | September 24, 2020

KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors. KYAN has already commenced preclinical development of the lead candidate, which has been designated as KYAN-001, with early positive results. In vitro and in vivo studies of KYAN-001 have shown high efficacy for Multiple Myeloma and Prostate ...

Read More
news image

Industry Outlook

ATTOVIA THERAPEUTICS LAUNCHES WITH $60 MILLION SERIES A FINANCING TO UNLOCK POTENTIAL OF NOVEL BIPARATOPIC NANOBODY PLATFORM

Globenewswire | June 21, 2023

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of diseases, and Frazier Life Sciences, announced the launch of Attovia Therapeutics, a newly formed company focused on creating a pipeline of biotherapeutics in immune-mediated disease and cancer. The company, based on Attobody™, Alamar’s novel proprietary biparatopic nanobody platform, concurrently closed a $60 million Series A financing led by Frazier and joined by venBio and Illumin...

Read More
news image

MedTech

ROCHE SIGNS AN AGREEMENT WITH SYSMEX TO BRING HAEMATOLOGY TESTING INNOVATIONS GLOBALLY

Roche | January 25, 2021

Roche declares that, on 14 December, 2020, it marked a Global Business Partnership Agreement* (GBP) with Sysmex. Under this new system, the gatherings restored their obligation to the long standing Distribution, Sales and Service (DSS) arrangement, permitting Roche to keep on disseminating Sysmex hematology items, including instruments and reagents. This GBP sees the presentation of an IT Solutions Collaboration Agreement. In the recently characterized joint effort, the two organizations have co...

Read More
news image

Cell and Gene Therapy, Industrial Impact

BIO-TECHNE ANNOUNCES COMPLETION OF AND GENE THERAPY CATAPULT ANALYTICAL TECHNOLOGY (PAT) CONSORTIUM

Bio-Techne Corporation | March 20, 2023

Bio-Techne Corporation announced it has completed its participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year collaboration involving 24 partner companies, technology providers, therapy developers, and charities. The Catapult PAT consortium is the first initiative of this scale and functional expertise with member companies and organizations collaborating to develop cell and gene therapy-specific process analytical technolog...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us